Table 3.

Effect of combined active specific IT and CT on tumor growth and/or survival in experimental animals

5-FC 5-fluorocytosine, 5-FU 5-fluorouracil, Ab antibody, Ad adenovirus, Ag antigen, AML acute myelogenous leukemia, BCG Bacillus Calmette Guerin, BCNU 1, 3-bis-(2-chloroethyl)-1-nitrosourea, CDC complement-dependent cytotoxicity, CFA complete Freund’s adjuvant, cFGFR chicken fibroblast growth factor receptor, CH-DOX chitosan hydrogel containing doxorubicin, CT chemotherapy, CTL cytotoxic T lymphocyte, CY cyclophosphamide, DC dendritic cells, DOX Doxorubicin, GITR glucocorticoid-induced TNFR family-related receptor, HPV human papilloma virus, i.m. intramuscularly, IT immunotherapy, LAMP lysosome-associated membrane protein, MTX methotrexate, NT not tested, pfu plaque forming units, s.c. subcutaneously; SINCP Sindbis virus, TIL tumor infiltrating lymphocytes, VEGFR vascular endothelial growth factor receptor, VRP Venezuelan equine encephalitis virus replicon particles